Trial Profile
A retrospective, multicenter study of eculizumab for the treatment in severe Shiga-toxin-secreting Escherichia coli infection in pediatrics
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2019
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Haemolytic uraemic syndrome; Shiga-toxigenic Escherichia coli infections
- Focus Therapeutic Use
- 17 Oct 2019 New trial record.